The role of signal transducer and activator of transcription factors in leukemogenesis
- PMID: 14722044
- DOI: 10.1200/JCO.2004.10.124
The role of signal transducer and activator of transcription factors in leukemogenesis
Abstract
Human leukemias are frequently associated with the aberrant expression of activated fusion tyrosine kinases or activated protein tyrosine kinases carrying insertional or point mutations. The activated kinase enzymes typically phosphorylate one or more signal transducer and activator of transcription (STAT) factors, which translocate to the cell nucleus and regulate the expression of genes associated with survival and proliferation. The phosphorylation and activation of STAT family members has been described in a wide range of human leukemias. Furthermore, animal models of leukemia have demonstrated the pivotal contribution of STAT activation to leukemic pathogenesis. This review discusses evidence for the functional importance of STAT activation in the biology of leukemia and current opportunities for modulating STAT proteins in the therapy of this group of diseases.
Similar articles
-
Vav transformation requires activation of multiple GTPases and regulation of gene expression.Mol Cancer Res. 2004 Dec;2(12):702-11. Mol Cancer Res. 2004. PMID: 15634759
-
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.Nat Clin Pract Oncol. 2005 Jun;2(6):315-24. doi: 10.1038/ncponc0195. Nat Clin Pract Oncol. 2005. PMID: 16264989 Review.
-
ETV6: a versatile player in leukemogenesis.Semin Cancer Biol. 2005 Jun;15(3):162-74. doi: 10.1016/j.semcancer.2005.01.008. Semin Cancer Biol. 2005. PMID: 15826831 Review.
-
Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling.J Allergy Clin Immunol. 2004 Sep;114(3):476-89; quiz 490. doi: 10.1016/j.jaci.2004.06.042. J Allergy Clin Immunol. 2004. PMID: 15356544 Review.
-
The role of constitutively active Stat6 in leukemia and lymphoma.Crit Rev Oncol Hematol. 2006 Mar;57(3):245-53. doi: 10.1016/j.critrevonc.2005.08.005. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16213149 Review.
Cited by
-
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.Cancer Sci. 2015 Jul;106(7):896-901. doi: 10.1111/cas.12683. Epub 2015 May 25. Cancer Sci. 2015. PMID: 25912076 Free PMC article. Clinical Trial.
-
The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.Cancers (Basel). 2018 Sep 13;10(9):327. doi: 10.3390/cancers10090327. Cancers (Basel). 2018. PMID: 30217007 Free PMC article. Review.
-
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.Mol Cancer Ther. 2014 May;13(5):1194-205. doi: 10.1158/1535-7163.MCT-13-0341. Epub 2014 Jan 16. Mol Cancer Ther. 2014. PMID: 24435449 Free PMC article.
-
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.Haematologica. 2016 Oct;101(10):1190-1199. doi: 10.3324/haematol.2015.136002. Epub 2016 Jul 14. Haematologica. 2016. PMID: 27418650 Free PMC article.
-
STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation.J Clin Pathol. 2007 Feb;60(2):173-9. doi: 10.1136/jcp.2005.035113. J Clin Pathol. 2007. PMID: 17264243 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical